Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Plays Up R&D Productivity With Reorganization

Executive Summary

Teetering on the brink of a vast patent cliff, Eli Lilly announced a reorganization and cost-cutting initiative Sept. 14. The program - intended to cut $1 billion in costs by the end of 2010 - is as much about enhancing R&D productivity as creating a leaner organization, according to the company

You may also be interested in...



Pursuit Of R&D Efficiency Continues As Regulatory Options Expand In 2013 – Tufts CSDD

Cutting non-core procedures – such as those supporting exploratory endpoints – from study budgets could save the industry $6 billion a year in drug development costs, the Tufts Center for the Study of Drug Development suggests in its 2013 industry outlook report.

Empire State Of Mind: Lilly Aims To Build Academic Ties With N.Y. Research Center

Eli Lilly & Co. gained a foothold in New York with its acquisition of ImClone Systems Inc. in 2008. Now it's looking to make more of a splash in the city and strengthen ties with local academic powerhouses by taking up residence in a new state-of-the-art biotech facility.

Empire State Of Mind: Lilly Aims To Build Academic Ties With N.Y. Research Center

Eli Lilly & Co. gained a foothold in New York with its acquisition of ImClone Systems Inc. in 2008. Now it's looking to make more of a splash in the city and strengthen ties with local academic powerhouses by taking up residence in a new state-of-the-art biotech facility.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel